These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19070529)

  • 1. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies.
    Sulpice M; Deslandre CJ; Quartier P
    Joint Bone Spine; 2009 Jan; 76(1):24-7. PubMed ID: 19070529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis.
    Brocq O; Millasseau E; Albert C; Grisot C; Flory P; Roux CH; Euller-Ziegler L
    Joint Bone Spine; 2009 Jul; 76(4):350-5. PubMed ID: 19362504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM; Burgos-Vargas R; Laxer RM
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.
    Scrivo R; Conti F; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
    Reumatismo; 2009; 61(2):107-17. PubMed ID: 19633797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France.
    Saint Marcoux B; De Bandt M;
    Joint Bone Spine; 2006 Dec; 73(6):710-3. PubMed ID: 17127088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: a twelve-year "real life" experience.
    Soubrier AS; Bele-Philippe P; Cortet B; Ramdane-Sebbane N; Bacle-Boutry MA; Lemeunier L; Flipo RM; Paccou J
    Joint Bone Spine; 2015 Jan; 82(1):31-7. PubMed ID: 25311253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
    Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Spondylarthropathies and anti-TNFalpha drugs].
    Pavy S; Allanore Y; Kahan A
    Rev Med Interne; 2005 Sep; 26(9):717-24. PubMed ID: 16154026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.
    Pham T; Fautrel B; Dernis E; Goupille P; Guillemin F; Le Loët X; Ravaud P; Claudepierre P; Miceli-Richard C; de Bandt M; Breban M; Maillefert JF; Masson C; Saraux A; Schaeverbeke T; Wendling D; Mariette X; Combe B;
    Joint Bone Spine; 2007 Dec; 74(6):638-46. PubMed ID: 18065252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
    Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and safety of TNFα antagonist therapy in 475 consecutive outpatients (with rheumatoid arthritis or spondyloarthropathies) treated by a single physician according to their eligibility for clinical trials.
    Berthelot JM; Benoist-Gérard S; le Goff B; Muller-Chevalet F; Maugars Y
    Joint Bone Spine; 2010 Dec; 77(6):564-9. PubMed ID: 20621538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.
    Wendling D; Balblanc JC; Briançon D; Brousse A; Lohse A; Deprez P; Humbert P; Aubin F
    Joint Bone Spine; 2008 May; 75(3):315-8. PubMed ID: 18329935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.